|Articles|July 13, 2012

LCMS-8080 triple quadrupole for LC/MS/MS analysis of complex matrices

Shimadzu has introduced the new LCMS-8080 triple quadrupole mass spectrometer which provides outstanding sensitivity with a large dynamic range and quantitation per-formance.

LCMS-8080 triple quadrupole for LC/MS/MS analysis of complex matrices

Shimadzu has introduced the new LCMS-8080 triple quadrupole mass spectrometer which provides outstanding sensitivity with a large dynamic range and quantitation per-formance. The special design generates higher ion efficiency with further reduction of background noise, making the LCMS-8080 the preferred instrument for applications needing the highest level of sensitivity for analysis of complex matrices.

The system completes Shimadzu’s LCMS triple quadrupole family (LCMS-8030 and -8040) and enables customers to choose the best instrument solution for their demands with the smallest footprint on the market. Combined with the reliable and well-established Shimadzu HPLC / UFLC front end systems already known as the fastest sys-tems with lowest carry-over market-wide, it is the perfect solution.

The excellent sensitivity is based on technologies such as Coaxial Hot gas providing efficient ionization, while HSID (Hot Source Induced Desolvation) removes neutral con-taminants and ensures reliable introduction of the ions into the mass spectrometer. The Laminar Flow technology conveys large quantities of ions to the detector with high transmission efficiency at high speeds.

Detection limits are in the low femtogram range. The LCMS-8080’s sensitivity range is wider with higher accuracy quantitation than ever before achieved.

The LCMS triple quadrupole family is controlled by the well-known innovative and easy-to-use LabSolutions software. It provides seamless operation and a stress-free analysis environment. The refined Quantitation Browser which processes multiple analytes is a powerful function for quantitative analysis. The Data Browser enables users to analyze and compare multiple sets of data in the same window.

For more information please visit www.shimadzu.eu.

Related to this article

PharmTech Weekly Roundup—October 2, 2026
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 1
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Regulatory Roundup—September 2026
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.